A5040798556- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Nutrition and Health in Aging
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Glycosylation and Glycoproteins Research
- Head and Neck Surgical Oncology
- Colorectal and Anal Carcinomas
Rush University Medical Center
2016-2025
Rush University
2014-2025
Memorial Sloan Kettering Cancer Center
2022
Genomics England
2020
RELX Group (United States)
2020
University of Chicago
2007-2018
Carolinas Healthcare System
2015
Levine Cancer Institute
2015
Georgetown University
2014
Providence Portland Medical Center
2014
Significance Immunotherapy has revolutionized cancer treatment, yielding unprecedented long-term responses and survival. However, a significant proportion of patients remain refractory, which correlates with the absence immune-infiltrated (“hot”) tumors. Here, we observed that FDA-approved unadjuvanted seasonal influenza vaccines administered via intratumoral injection not only provide protection against active virus lung infection, but also reduce tumor growth by increasing antitumor CD8 +...
Abstract Background Recurrent head and neck squamous cell carcinoma (rHNSCC) represents a significant global health burden with an unmet medical need. In this study we determined the safety efficacy of RM‐1929 photoimmunotherapy in patients heavily pretreated rHNSCC. Methods (anti‐EGFR–IR700 dye conjugate) was infused, followed by tumor illumination. We evaluated safety, response, pharmacokinetics. Results Nine were enrolled Part 1 (dose‐finding) 30 2 (safety efficacy). No dose‐limiting...
BackgroundIn KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes based on PD-L1 expression archival newly collected tumor samples using recently updated data.Patients and methodsPD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) or samples. Patients received 2 10 mg/kg Q3W 75 mg/m2 for 24...
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with protease-cleavable linker and peptide mask that limits target engagement in normal tissue circulation. The tumor microenvironment enriched for proteases capable of cleaving the linker, thereby releasing mask, allowing localized binding CX-2009 CD166. was evaluated phase I/II clinical trial patients advanced solid tumors.Eligible had metastatic...
Immune checkpoint inhibitors (ICIs) have uncommon associations with cardiotoxicity, yet these cardiotoxic effects are associated high mortality. An accurate assessment of risk for cardiotoxicity is essential clinical decision-making, but data from randomized controlled trials often differ real-world observational studies.
PURPOSE Preclinical studies demonstrated that dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial (VEGF) pathways delay the emergence resistance to EGFR tyrosine kinase inhibitors (TKIs), in trials with first-generation TKIs, combination VEGF pathway prolonged progression-free survival (PFS). METHODS The RAMOSE trial (ClinicalTrials.gov identifier: NCT03909334 , HCRN LUN-18-335) is a randomized, open-label multicenter phase II study comparing osimertinib...
The primary objective of this study is to identify prognostic site-specific epigenetic changes in surgically treated Stage I and II nonsmall cell lung cancer (NSCLC) patients by quantifying methylation levels at multiple CpG sites within each gene promoter. Paraffin-embedded tumors from stage Ib, IIa IIb training validation groups 75 57 NSCLC patients, respectively, were analyzed for p16, MGMT, RASSF1, RASSF5, CDH1, LET7, DAPK PTEN promoter hypermethylation. Hypermethylation status was...
There is emerging evidence showing a significant relationship between overall survival (OS) in non-small cell lung cancer NSCLC patients and weight change during chemotherapy or chemoradiation. A high neutrophil/lymphocyte ratio (NLR) at baseline follow-up associated with shorter may be surrogate for ongoing inflammation, implicated cachexia tumor progression. The objective of this study to explore potential relationships OS, serial weights, NLRs advanced receiving chemotherapy. One hundred...
In ADAURA, adjuvant osimertinib significantly improved disease-free survival versus placebo in resected stage IB to IIIA EGFR-mutated NSCLC. We report in-depth analyses of three-year safety, tolerability, and health-related quality life (HRQoL) from ADAURA.Patients were randomized 1:1 80 mg or once daily for up 3 years. Safety assessments performed at baseline, week 2, 4, 12, every 12 weeks until treatment completion discontinuation, 28 days after was stopped. The SF-36 survey measured HRQoL...
The insulin-like growth factor (IGF) pathway is a complex involving interactions between membrane-bound receptors, ligands, binding proteins, downstream effectors, and other receptor tyrosine kinase signaling cascades. IGF has been identified as potential therapeutic target in non-small cell lung cancer (NSCLC) based on the following provocative factors. Preclinical observations NSCLC have shown that this involved tumor proliferation, survival, invasiveness. In addition, IGF-1R protein...
The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used predict differential benefit from erlotinib versus chemotherapy previously treated advanced non-small cell lung cancer (NSCLC). Multiple studies highlight the clinical utility of test, however, mechanistic connection between VeriStrat-poor classification poor prognosis untreated patients still an active area research. aim this study was correlate...
8509 Background: The PACIFIC trial demonstrated that a year of consolidation PD-(L)1 inhibition following concurrent chemoradiation (CRT) for unresectable stage III NSCLC improves overall survival (OS). optimal duration IO therapy in this setting is undefined. Studies metastatic demonstrate combination PD-(L)1/CTLA-4 OS over chemotherapy alone. This evaluated the use Nivolumab (N) plus Ipilimumab (IPI) or N alone up to 6 months after CRT. Methods: randomized phase II, multicenter 105 pts...
Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor effects of erlotinib in preclinical studies, and COX-2 is frequently expressed non-small cell lung cancer (NSCLC). With these observations, we designed phase II trial to evaluate the efficacy safety plus celecoxib advanced NSCLC.Previously treated stage IIIB/IV NSCLC patients were given at 400 mg orally twice daily 150 until disease progression. Planned accrual was 40 patients. Tissue collected for epidermal growth factor...
Definitive chemoradiotherapy is a core treatment modality for patients with stage III non-small cell lung cancer (NSCLC). Although radiotherapy (RT) technologies have advanced dramatically, to the authors' knowledge relatively little known regarding importance of irradiation technique on outcome, particularly given competing risk distant metastasis. The National Cancer Data Base was used determine predictors overall survival (OS) in AJCC NSCLC who were treated chemoradiotherapy, focusing...
First-line treatment for patients with non-small cell lung cancer (NSCLC) a sensitizing epidermal growth factor receptor (EGFR) mutation is tyrosine kinase inhibitor (TKI). Despite higher response rates and prolonged progression free survival (PFS) compared platinum doublet chemotherapy, subset of these do not receive benefit from agents. We investigate if the neutrophil-to-lymphocyte ratio (NLR) other markers cachexia chronic inflammation correlate worse outcomes in patients.This study...
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
Abstract Approximately 30% of patients (pts) with non-small cell lung cancer (NSCLC) have alterations in the KRAS oncogene. In NSCLC mutational variants are diverse and therapeutically relevant. However, it is unclear how each variant associated tumor biology, including lipid metabolism immune microenvironment. Since perturbed infiltration linked to outcomes, we evaluated characterized association infiltration. Using Tempus Database, 5, 925 de-identified records from pts (G12A (n=464), G12C...